Q/C Technologies closed at $0.39 on Nov 4, down 8.00%, within 0.0% of its 52-week closing low. Volume of 167.0K shares was 0.96× its 20-day average (close to normal).
Split-adjusted performance: -43.3% over one month, -90.2% over six months, -88.4% over one year.
Short interest was 997.4K shares at the Oct 15 settlement, up 5.2% from the prior report (12.2% of float, 3.6 days to cover).
No reported quarters with price history yet.
Percentile among 15 companies (100 = best)
Industry medians: 6-month return +17.4%, revenue growth −2.0%, net margin −26.0%, P/E 46.6×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| QCLSQ/C Technologies | $0.3910 | −8.00% | −90.2% | — | — | — | $3.2M | |
| CDIOCardio Diagnostics Holdings | $1.65 | +2.81% | −9.6% | −28.3% | −28012.5% | — | $4.9M | Compare |
| VNRXVolitionRx Limited | $0.2031 | +5.23% | −91.8% | −2.0% | −1953.1% | — | $6.1M | Compare |
| BMRABIOMERICA | $1.74 | +2.06% | −21.5% | −8.3% | −97.4% | — | $8.0M | Compare |
| IMDXInsight Molecular Diagnostics | $2.65 | −3.28% | −47.3% | −53.9% | −4711.3% | — | $86.7M | Compare |
| ICCCImmucell | $10.37 | +1.17% | +19.7% | +11.5% | 25.5% | 119.6 | $94.2M | Compare |
| TKNOAlpha Teknova | $7.37 | +0.41% | +102.5% | +18.5% | −26.0% | — | $454.7M | Compare |
| MYGNMyriad Genetics | $6.02 | −0.33% | +46.5% | −10.5% | −22.7% | — | $575.8M | Compare |
| ACHVAchieve Life Sciences | $6.98 | +3.71% | +45.4% | — | — | — | $719.7M | Compare |
Q/C Technologies Inc is engaged in building blockchain and cryptocurrency infrastructure that is faster and more energy-efficient through quantum-class laser-based computing. The company uses laser-based processors inspired by quantum technology that can solve complex problems. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
